Sign In

Alexander Varond

FDA Partner & FDA Litigation Co-Chair, Goodwin Life Sciences

Alexander Varond is a prominent figure in the field of FDA regulatory law and litigation. He serves as a Partner at Goodwin and holds the position of Co-Chair of the firm's FDA Litigation practice.1 His expertise spans across various aspects of the life sciences and technology sectors, with a particular focus on advising clients in the pharmaceutical, biotechnology, and medical device industries.1

Professional Background

Alexander's career is characterized by a unique blend of technical and legal expertise:

  • Current Role: Partner in Goodwin's Technology and Life Sciences groups and Co-Chair of the FDA Litigation practice1
  • Previous Experience: Senior Associate at Hyman, Phelps & McNamara, PC before joining Goodwin in 20171
  • Industry Experience: Worked as a medical device engineer, operations manager, and deputy management representative to the FDA1

Areas of Expertise

Alexander's practice covers a wide range of FDA regulatory matters, including:

  • Drug and medical device development
  • Hatch-Waxman patent and exclusivity issues
  • Regulatory strategy
  • Advertising and promotional issues
  • Civil and criminal investigations
  • Corporate transactions1

Recognition and Achievements

Alexander has received numerous accolades for his work:

  • Named a Top Healthcare Lawyer by the Daily Journal in 20233
  • Recognized in The Best Lawyers in America for FDA Law (2022-2023)
  • Listed as a "Rising Star" in Food & Drug Law by Super Lawyers (2019-2023)
  • Acknowledged as a "Next Generation Partner" in Healthcare: Life Sciences by The Legal 500 United States (2022-2023)1

Education and Bar Admissions

  • Education: J.D. from The George Washington University Law School; B.S. in Biomedical Engineering and Management Science from the University of California, San Diego1
  • Bar Admissions: District of Columbia and California1

Alexander Varond's LinkedIn username is indeed avarond, as mentioned in the query.2

Highlights

Jul 6 · linkedin

I'm incredibly excited to continue making a splash in California healthcare and life sciences, this time being named a Top Healthcare Lawyer by Daily Journal Corporation! The West Coast is an important, vibrant, and rapidly growing market--and it's also pretty unique. It's a true honor to be a part of the team at Goodwin working with these talented folks to drive innovation and patient-focused care.

May 19 · linkedin

FDA just made public its Lumryz letter decision on orphan drug exclusivity and clinical superiority. Worth a read for anyone in the orphan/Hatch Waxman space, especially for its in-depth discussion of major contribution to patient care (MCTPC). For example:

"Nonetheless, FDA has concluded that Lumryz is clinically superior to Xywav as a MCTPC given the benefit of Lumryz’s once-nightly dosing despite Xywav’s greater safety due to reduced sodium. First, as explained above, there is no requirement for comparable safety when making a MCTPC finding, and finding clinical superiority based on one parameter — greater safety, greater efficacy, or a MCTPC — is sufficient to meet the clinical superiority standard."

"FDA does not require direct comparative clinical trials to demonstrate that a drug makes a MCTPC."

https://lnkd.in/g_dgWqqV #fda

Related Questions

What are some notable cases Alexander Varond has worked on?
How does Alexander Varond's background in engineering influence his legal practice?
What are the key areas Alexander Varond focuses on in FDA litigation?
How has Alexander Varond's work impacted the pharmaceutical industry?
What awards or recognitions has Alexander Varond received in his career?
Alexander Varond
Alexander Varond, photo 1
Alexander Varond, photo 2
Add to my network

Location

San Francisco, California, United States